Generic firms could face hurdles in showing that their opioid products have abuse deterrence properties comparable to the innovator product, stakeholders suggest in response to FDA's draft guidance.
Edward Cone, principal scientist, drug delivery and abuse-deterrent drug products at PinneyAssociates, said the agency's call for generic companies to first evaluate the reference listed drug versus a control without...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?